- Report
- May 2025
- 220 Pages
Global
From €2216EUR$2,500USD£1,926GBP
- Report
- September 2024
- 291 Pages
Global
From €4388EUR$4,950USD£3,814GBP
- Report
- September 2024
- 142 Pages
Global
From €2658EUR$2,999USD£2,311GBP
- Report
- January 2023
- 281 Pages
Global
From €4703EUR$5,491USD£3,950GBP
- Report
- May 2023
- 193 Pages
Global
From €4388EUR$4,950USD£3,814GBP
- Report
- August 2023
- 150 Pages
Global
From €2881EUR$3,250USD£2,504GBP
€4299EUR$4,850USD£3,737GBP
- Report
- November 2023
- 160 Pages
Global
From €3944EUR$4,450USD£3,429GBP
- Report
- November 2022
- 114 Pages
Global
From €3390EUR$3,825USD£2,948GBP
€3989EUR$4,500USD£3,468GBP
- Report
- April 2024
- 71 Pages
Europe
From €3058EUR$3,450USD£2,659GBP
- Report
- April 2024
- 68 Pages
North America
From €3058EUR$3,450USD£2,659GBP
The Human Microbiome Therapeutics market is a subset of the biopharmaceuticals industry that focuses on the development of treatments and therapies that target the human microbiome. The human microbiome is the collection of microorganisms that live in and on the human body, and is increasingly being recognized as an important factor in human health. The Human Microbiome Therapeutics market is focused on developing treatments and therapies that target the microbiome, such as probiotics, prebiotics, and fecal microbiota transplants. These treatments are used to treat a variety of conditions, including gastrointestinal disorders, metabolic disorders, and autoimmune diseases.
Companies in the Human Microbiome Therapeutics market include Seres Therapeutics, Second Genome, Enterome Bioscience, and Rebiotix. Show Less Read more